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A 38-year-old man with acute myocardial infarction
in the lower wall affecting the right ventricle underwent
thrombolytic treatment with streptokinase. Approximate-
ly 2 hours after the thrombolytic treatment started, he pre-
sented with signs of coronary reocclusion. He underwent
emergency cineangiocoronariography that revealed that
his right coronary artery was completely occluded by a
clot. He unsuccessfully underwent angioplasty and stent
implantation. After the concomitant use of glycoprotein
IIb/IIIa inhibitor, coronary TIMI III flow was achieved wi-
thout additional dilations, and he was discharged from
the hospital 5  days later with no further complications.
Antiplatelet therapy for acute coronary syndrome is
widely established 1. As for acute myocardial infarction, the
data from the ISIS 2 study showed clearly that acetylsalicylic
acid, alone and/or combined with thrombolytic therapy with
streptokinase, plays a role in the reduction of mortality 2. Over
the last few years, important progress has been made in this
field as new and stronger antiplatelet drugs, such as the gly-
coprotein IIb/IIIa inhibitors, have been discovered. Howe-
ver, the role of these new medications as a primary support
therapy in acute myocardial infarction still needs to be better
understood.
Case Report
A 38-year-old male patient, smoker, previously in good
health, came to the emergency  department complaining of a
4-hour-long oppressive retrosternal pain that had started du-
ring intense exercise, irradiating to the left upper limb, accom-
panied by dyspnea, sweating and vomiting, which improved
slightly after sublingual nitrate and aspirin administration.
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On admission, he was tachypneic, with a blood pressu-
re of 130x80mmHg and a heart rate of 80 bpm, normal pulmo-
nary auscultation, and a regular heart pace of three beats at
the  4th sound, without murmurs. Pulses were symmetrical, and
no jugular stasis was present. The electrocardiogram showed
an AV dissociation, an overunlevelling of 8mm of the ST
portion at D
2
, D
3
, and the VF and of 4 mm at V
2
 to V
6
, V
3
R, V
4
R,
V
7
, and V
8
, and an underunlevelling  at D
1
, VL, and VR (fig. 1).
An acute myocardial infarction was diagnosed, and 20
minutes later thrombolysis with 1,500,000 U of endovenous
streptokinase was administered for 40 minutes. The patient
reported moderate pain relief and had a slight reduction in
the overunlevelling of the ST portion, while the AV disso-
ciation persisted. Approximately 2 hours later, he developed
recurrent pain, without any change in the initial electrocar-
diographic alterations. After the introduction of low-dose
endovenous nitroglycerin, he experienced a slight improve-
ment, but about an hour later, he again felt intense pain,
which persisted even with nitroglycerin use, so an emergen-
cy heart catheterization was performed. Prior to this test,
with persistent pain, the patient developed significant hy-
potension accompanied by jugular stasis and slight stertors
at the lung bases, requiring dobutamine, even after adequa-
te volemic repositioning. The procedure was started appro-
ximately 10 hours after the infarction began to develop.
The left coronariography showed no atherosclerotic
lesions. The right coronariography showed a dominant,
gross-caliber right coronary artery to be totally occluded
at its proximal third (fig. 2). A guiding lead was threaded to
the distal third of the right coronary artery without any
difficulty. Then, insufflation with a 3.5x20mm balloon was
performed for 2 minutes. The control coronariography
(fig. 3) showed a TIMI II flow and a type B dissection at the
balloon insufflation site. It was then decided to implant a
4.0x15mm NIR stent, which was done with no difficulty.
Afterwards, a control coronariography was performed
that showed the right coronary artery to be totally oc-
cluded where the stent had been placed (fig. 4). The
patient was still hypotensive, slightly dyspneic, tachy-
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cardic, and with precordial pain. We chose to perform
further dilations at several places, with pressure of up to
18 atm, at the stent site, but were unsuccessful. At this
point, activating cloting time (ACT) was 300 s, and we
decided to use abciximab, in the usual dose. Ten minutes
after the bolus, the flow was re-established, but with a
clot at the medium and distal thirds of the right coronary
(fig. 5), and 30 minutes after continuous infusion, the ves-
sel had a TIMI 3 flow, but clots were still present (fig. 6).
After 90 minutes, TIMI 3 flow returned and no signs of dis-
section or clot (fig. 7) were present. After the introduction
of abciximab, no additional insufflation was performed.
Fig. 1 – Patient’s electrocardiogram on admission, showing overunlevelling of the ST segment at D
2
, D
3
, and the VF, V
2
 to V
6
, V
3
R, V
4
R, V
7
 and V
8
, and underunlevelling at D
1
,
VL, and VR.
Fig. 2 – Completely occluded right coronary artery after thrombolysis by
streptokinase.
Fig. 3 – Right coronary artery after balloon insufflation, showing type B dissec-
tion at its medium third.
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Fig. 6 – Right coronary artery 30 minutes after continuous abciximab infusion, sho-
wing TIMI III flow, but still with a clot.
Fig. 7 – Right coronary artery 90 minutes after continuous abciximab infusion, with
TIMI III flow, without an intraluminal clot.
The patient’s pain resolved and he was transferred to
the coronary unit, where he stayed on continuous abcixi-
mab infusion for another 12 hours, being discharged from
the hospital 5 days later, with no symptom recurrence.
Discussion
Ever since the results of the GISSI 1 study with strepto-
kinase and the ASSET 2 study with r-TPA were published,
the reduction in mortality by thrombolytic therapy in cases
of acute myocardial infarction with overunlevelling of the
ST segment has been established. However, depending on
the thrombolytic agent used, the patency of the vessel, de-
fined as TIMI II and III flows, varies in 60% to 80% of the
treated patients 3,4. When the full flow of the vessel res-
ponsible for the infarction (TIMI III flow) is considered, this
goal is achieved in no more than 30% to 50% of the treated
patients 4. Even after successful thrombolytic therapy,
about 5% to 10% of the patients have their reperfused ves-
sel reoccluded, and, as a consequence, reinfarction and an
increase in morbidity and mortality occur 5, 6.
In our case, after successful thrombolytic therapy with
streptokinase, the patient again showed signs of reocclu-
sion, confirmed by cineangiocoronariography.
After this confirmation, the patient underwent rescue
angioplasty with implantation of a stent and additional dila-
tions, which were unsuccessful. Because coronary rethrom-
bosis occurred, despite full anticoagulation with heparin
and systemic fibrinolysis produced by streptokinase, the
glycoprotein IIb/IIIa inhibitor was then successfully used.
In such circumstances, rapid decision making is crucial, and
basically 2 options are possible: the surgical one, with all
Fig. 4 – Completely occluded right coronary artery after stent implantation.
Fig. 5 – Right coronary artery 10 minutes after the abciximab bolus, with re-establi-
shed flow and an intraluminal clot.
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the risks inherent to systemic fibrinolysis determined by
streptokinase, and the use of a glycoprotein IIb/IIIa inhibi-
tor, being equally aware of the risks possible with this com-
bination. As the patient had only one severely injured arte-
ry, the latter option was chosen.
Therapy with glycoprotein IIb/IIIa inhibitors was ana-
lyzed in different clinical situations, and its benefits
(reduction in ischemic events) were proven in high- and low-
risk percutaneous therapeutic procedures, resistant unsta-
ble angina and in cases of acute myocardial infarction pri-
marily treated by angioplasty.
Until now, only the endovenously given GPIIb/IIIa in-
hibitors have proved effective in reducing major cardiac
events. Studies that analyzed the GPIIb/IIIa inhibitors given
orally in acute myocardial infarction without the Q-wave
and in unstable angina and in invasive therapeutic proce-
dures showed negative results with regard to its benefits 7,8.
Some phase II studies analyzed, as a primary treatment for
acute myocardial infarction, associated with thrombolytic
therapy, the use of Integrilin with r-TPA (IMPACT-AMI) 9,
lamifiban with streptokinase or r-TPA (PARADIGM), and
abciximab with r-TPA or streptokinase (TIMI 14) 10. Howe-
ver, in dose analysis studies, such as TIMI 14, where 14 the-
rapeutic regimes were studied, it was shown that, in the
group that used 50mg TPA with the usual dose of abciximab,
the TIMI III flow was reached in 72% of cases after 60 minu-
tes. In the group whose thrombolytic regime was a full dose
of streptokinase, the incidence of hemorrhage was prohibi-
tive, only 5 patients being included 4 of whom had signifi-
cant bleeding, and 2 died. In our case, the patient was in an
unfavorable hemodynamic condition, abciximab therapy
was chosen in spite of the risk of bleeding, and the result of
the procedure was successful, with full flow resumed in the
artery responsible for the infarction, without any additional
dilation after the start of the GPIIb/IIIa inhibitor.
Sakharov and Rijken 11 demonstrated that continuous
activation of plasminogen may be necessary if complete re-
perfusion is the goal. But this occurs more markedly with
streptokinase than with the other thrombolytic drugs, thus
increasing the risks of this therapy. Coronary thrombosis si-
multaneously involves deposition and lysis of fibrin and
platelets, causing intermittent occlusions. According to the
results of the recently published SPEED 12 study, the associ-
ation of small doses of a thrombolytic agent with a strong
platelet inhibitor appears to enhance fibrin and platelet lysis,
producing more adequate reperfusion. Since TIMI 14, it has
become clear that a high incidence of severe bleeding occurs
when the  combination of streptokinase and abciximab is
used, which makes this combination basically prohibitive. In
spite of a very interesting result, the risks should not be for-
gotten, so extreme  practices should only be adopted in very
special situations. The ongoing GUSTO 4 phase III study
will bring us a final answer concerning the use of this combi-
nation for treatment during the acute period of acute
myocardial infarction.
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